Log In
BCIQ
Print this Print this
 

VA111913 (formerly VT913)

  Manage Alerts
Collapse Summary General Information
Company Vantia Therapeutics Ltd.
DescriptionVasopressin 1a (V1a) receptor antagonist
Molecular Target Vasopressin 1 (V1) receptor
Mechanism of ActionVasopressin 1 (V1) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationDysmenorrhea
Indication DetailsTreat dysmenorrhea
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today